Semaglutide
5 mg
$39.00
Cagrilintide is a long-acting acylated amylin analogue that acts on amylin and calcitonin receptors, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
For use by licensed and trained professionals only, operating within their applicable regulations. Not evaluated by the FDA.
Cagrilintide is a long-acting acylated amylin analogue that acts on amylin and calcitonin receptors, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg — $59.00 · 10 mg — $99.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 4409.0 g/mol |
| CAS | 1415456-99-3 |
| Sequence length | — |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | GLP-CAGRI |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, studied both as a standalone agent and in fixed-dose combination with semaglutide ("CagriSema") through the REDEFINE clinical-trial program.
Amylin is a pancreatic hormone co-secreted with insulin that acts on amylin and calcitonin receptors in the hindbrain to promote satiety and slow gastric emptying — a complementary pathway to GLP-1 receptor agonism. Cagrilintide's fatty-acid acylation extends its half-life to support once-weekly dosing in the studies conducted so far.
As a long-acting amylin analogue, it is a reference compound for research into amylin-receptor pathways as a complement to GLP-1-based approaches.
The REDEFINE trial program studies cagrilintide combined with semaglutide, comparing combined amylin/GLP-1 receptor agonism against single-agent therapy.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
No — it remains investigational, studied both alone and in the CagriSema combination with semaglutide. Not FDA-approved as of 2026.
Further reading: for the published preclinical and clinical literature on Cagrilintide, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.